Patents by Inventor Danielle Benoit
Danielle Benoit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230293704Abstract: The present invention generally relates to novel compositions and methods for promoting regeneration of injured tendon. In some aspects, the composition comprises a nanoparticle that targets specifically to injured tendon to deliver a therapeutic agent that promotes tendon regeneration. In certain aspects, the methods comprise administering to a subject in need thereof a nanoparticle that targets specifically to injured tendon to deliver a therapeutic agent that promotes tendon regeneration.Type: ApplicationFiled: January 27, 2023Publication date: September 21, 2023Inventors: Danielle Benoit, Alayna E. Loiselle, Emmanuela Adjei-Sowah
-
Patent number: 11707483Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.Type: GrantFiled: September 23, 2019Date of Patent: July 25, 2023Assignees: UNIVERSITY OF WASHINGTON, GENEVANT SCIENCES GMBHInventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
-
Publication number: 20210330599Abstract: The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.Type: ApplicationFiled: August 1, 2017Publication date: October 28, 2021Inventors: Danielle BENOIT, Hyun KOO
-
Publication number: 20200147121Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.Type: ApplicationFiled: September 23, 2019Publication date: May 14, 2020Applicants: University of Washington, GENEVANT SCIENCES GMBHInventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
-
Patent number: 10420790Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.Type: GrantFiled: April 27, 2017Date of Patent: September 24, 2019Assignees: University of Washington, GENEVANT SCIENCES GMBHInventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
-
Patent number: 10195284Abstract: The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3?. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation or treatment.Type: GrantFiled: September 26, 2016Date of Patent: February 5, 2019Assignee: UNIVERSITY OF ROCHESTERInventors: Danielle Benoit, J. Edward Puzas, Maureen Newman, Tzong-Jen Sheu, Benjamin Frisch
-
Publication number: 20180171056Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.Type: ApplicationFiled: November 30, 2017Publication date: June 21, 2018Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
-
Patent number: 9949950Abstract: The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3?. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation.Type: GrantFiled: September 14, 2015Date of Patent: April 24, 2018Assignee: UNIVERSITY OF ROCHESTERInventors: Danielle Benoit, J. Edward Puzas, Maureen Newman, Tzong-Jen Sheu
-
Patent number: 9862792Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.Type: GrantFiled: September 13, 2016Date of Patent: January 9, 2018Assignees: University of Washington, PhaseRx, Inc.Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
-
Publication number: 20170239360Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.Type: ApplicationFiled: April 27, 2017Publication date: August 24, 2017Applicants: University of Washington, PhaseRx, Inc.Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
-
Patent number: 9662403Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.Type: GrantFiled: March 2, 2016Date of Patent: May 30, 2017Assignees: University of Washington, PhaseRx, Inc.Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
-
Publication number: 20170096517Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.Type: ApplicationFiled: September 13, 2016Publication date: April 6, 2017Applicants: University of Washington, PhaseRx, Inc.Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
-
Publication number: 20170072062Abstract: The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3?. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation or treatment.Type: ApplicationFiled: September 26, 2016Publication date: March 16, 2017Inventors: Danielle Benoit, J. Edward Puzas, Maureen Newman, Tzong-Jen Sheu
-
Patent number: 9566247Abstract: The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.Type: GrantFiled: February 25, 2014Date of Patent: February 14, 2017Assignee: University of RochesterInventors: Hyun Koo, Danielle Benoit, Marlise I. Klein, Megan L. Falsetta Wood
-
Patent number: 9476063Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.Type: GrantFiled: May 13, 2009Date of Patent: October 25, 2016Assignees: University of Washington, PhaseRx, Inc.Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
-
Publication number: 20160250338Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.Type: ApplicationFiled: March 2, 2016Publication date: September 1, 2016Applicants: University of Washington, PhaseRx, Inc.Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
-
Patent number: 9339558Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.Type: GrantFiled: May 13, 2009Date of Patent: May 17, 2016Assignees: University of Washington, PhaseRx, Inc.Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Craig L. Duvall, Danielle Benoit, Robert W. Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
-
Publication number: 20150374663Abstract: The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3?. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation.Type: ApplicationFiled: September 14, 2015Publication date: December 31, 2015Applicant: UNIVERSITY OF ROCHESTERInventors: DANIELLE BENOIT, EDWARD J. PUZAS, MAUREEN NEWMAN, TZONG-JEN SHEU
-
Publication number: 20150374634Abstract: The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.Type: ApplicationFiled: February 25, 2014Publication date: December 31, 2015Applicant: UNIVERSITY OF ROCHESTERInventors: Hyun Koo, Danielle Benoit, Marlise I. Klein, Megan L. Falsetta Wood
-
Patent number: 9193954Abstract: Provided is a method for increasing proliferation of mesenchymal stem cells. The method entails contacting the cells with 6-bromoindirubin-3?-oxime (BIO). This results in robust proliferation and “stemness” in a dose-dependent fashion, as indicated by the gene expression of two stem cell genes: Sox2 and Nanog.Type: GrantFiled: April 2, 2012Date of Patent: November 24, 2015Assignee: University of RochesterInventors: Michael Hoffman, Danielle Benoit